Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Monday, April 27

Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease (4310)

Samuel Frank, Christina Vaughan, David Stamler, David Oakes, Mat D. Davis, Nicholas Gross, Mark Forrest Gordon, Juha-Matti Savola, Maria Wieman, Shirley Eberly, Elise Kayson, Jacquelyn Whaley, Jody Goldstein, Claudia M. Testa
First published April 14, 2020,
Samuel Frank
1Beth Israel Deaconess Medical Center/Harvard Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Vaughan
2University of Colorado
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Stamler
3Teva Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Oakes
4University of Rochester
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mat D. Davis
3Teva Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Gross
3Teva Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Forrest Gordon
3Teva Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juha-Matti Savola
3Teva Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Wieman
3Teva Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shirley Eberly
4University of Rochester
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elise Kayson
4University of Rochester
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacquelyn Whaley
5Center for Human Experimental Therapeutics, University of Rochester
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jody Goldstein
5Center for Human Experimental Therapeutics, University of Rochester
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia M. Testa
6Virginia Commonwealth University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease (4310)
Samuel Frank, Christina Vaughan, David Stamler, David Oakes, Mat D. Davis, Nicholas Gross, Mark Forrest Gordon, Juha-Matti Savola, Maria Wieman, Shirley Eberly, Elise Kayson, Jacquelyn Whaley, Jody Goldstein, Claudia M. Testa
Neurology Apr 2020, 94 (15 Supplement) 4310;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD.

Background: In the First-HD pivotal trial, the maximum deutetrabenazine dose evaluated to treat HD chorea was 48 mg/d, which is the approved maximum dose for this population. In ARC-HD, an open-label extension study evaluating the long-term efficacy and safety of deutetrabenazine to treat HD chorea, dosage ranged from 6 mg/d to 72 mg/d. Doses in ARC-HD were increased by 6 mg/d per week in a response-driven manner based on efficacy and tolerability until 48 mg/d (week 8), and, at investigator’s discretion, further increases were permitted by 12 mg/d per week to a maximum of 36 mg twice daily.

Design/Methods: In this post-hoc analysis, patient counts and safety assessments were attributed to patients when they received a dose either ≤48 mg/d or >48 mg/d. For 9 selected adverse events (AEs), we compared AE rates adjusted for duration of drug exposure (as number of AEs/year) at ≤48 mg/d or >48 mg/d. The AE rates were determined after titration when participants were on stable doses of deutetrabenazine.

Results: All 113 patients were exposed to doses ≤48 mg/d (177.1 patient-years), but only 49 subjects were ever exposed to doses >48 mg/d (74.1 patient-years). In patients taking deutetrabenazine >48 mg/d compared to ≤48 mg/d after the titration period, there were no apparent differences in exposure-adjusted AE rates.

Conclusions: Some patients with HD require doses higher than 48 mg/day to adequately control chorea. These doses were tolerated without apparent increase in the exposure-adjusted rates of selected AEs after titration. This analysis does not address the occurrence of other AEs or whether adequate efficacy was achieved at lower doses, factors that may have influenced dose increases.

Disclosure: Dr. Frank has received research support from First-HD, and ARC-HD.Dr. Vaughan has nothing to disclose. Dr. Stamler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Former employee of Teva Pharmaceuticals; salary and benefits from Auspex Pharmaceuticals. Patents pending: US20160346270, US20160287574.. Dr. Oakes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Research Support: Auspex (for the FIRST-HD and related studies), Vaccinex Inc., Prana Pharmaceuticals, Biogen, Inc., NIH. Honoraria: Raptor Pharmaceuticals, Voyager Inc.. Dr. Oakes has received research support from Research Support: Auspex (for the FIRST-HD and related studies), Vaccinex Inc., Prana Pharmaceuticals, Biogen, Inc., NIH. Honoraria: Raptor Pharmaceuticals, Voyager Inc..Dr. Davis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as an Employee of Teva Pharmaceuticals. Dr. Gross has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals, USA. Dr. Gordon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Savola has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Former employee of Teva Pharmaceuticals International, GmbH, Basel, Switzerland.. Dr. Wieman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Former employee of Teva Pharmaceuticals.. Dr. Eberly has nothing to disclose. Dr. Kayson has nothing to disclose. Dr. Whaley has nothing to disclose. Dr. Goldstein has nothing to disclose. Dr. Testa has received research support from Co-Principal Investigator: First-HD. Consultant: Lundbeck, with honoraria donated to the Medical College of Virginia Foundation.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise